{'fraction_non_alphanumeric': 0.030389363722697058, 'fraction_numerical': 0.02849002849002849, 'mean_word_length': 5.466257668711656, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 1, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Protection of human muscle acetylcholinesterase from soman by pyridostigmine bromide

Introduction: Pretreatment with pyridostigmine bromide (PB) of human intercostal muscle fibers exposed to the irreversible acetylcholinesterase (AChE) inhibitor soman was investigated. Methods: Muscles were pretreated with 3 × 10−6 M PB or saline for 20 minutes, then exposed to 10−7 M soman for 10 minutes. Results: AChE of muscles treated with soman alone was inhibited >95%. In contrast, PB pretreatment of soman‐exposed bundles protected 20% of AChE activity. AChE of bundles exposed to PB alone recovered after 4 hours, but bundles exposed to both PB and soman did not. Soman‐induced reduction of resting membrane potentials and increment of amplitudes and decay times of miniature endplate potentials (MEPPs) were partially corrected by PB pretreatment. Conclusions: In vitro pretreatment of human muscles with PB protected up to 20% of muscle AChE and ameliorated some deleterious effects on endplate physiology induced by soman. Muscle Nerve 43: 591–595, 2011